Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Disease area: Thoracic oncology

Abstract

Introduction:Several EGFR-specific molecular inhibitors are currently used in clinical oncology. Thus, the determination of EGFR status on protein level as well as the detection of EGFR mutations to identify patients who show high response rates towards TKIs, is essential. Up to now, common EGFR evaluation criteria are still missing, but absolutely necessary.Aims and objectives:To identify enlarged collectives of patients who might benefit from Tyrosine kinase inhibitors, in addition to those bearing activating mutations, we wanted to figure out which is the optimized method of EGFR expression evaluation on protein level in addition to the determination of gene amplification status.Methods:206 tumor tissues were analyzed in a tissue microarray format employing immunohistochemistry (IHC) with four different antibodies including Dako PharmDx kit (clone 2-18C9), clone 31G7, clone 2.1E1 and clone SP84 using three different scoring methods. Protein expression was compared to fluorescence in situ hybridization (FISH) using two different probes. Data of IHC and FISH-analysis were further correlated with clinicopathological data to find out, whether IHC could be the method of choice, probably coupled to FISH-analysis.Results:Two different FISH probes revealed identical gene amplification status in NSCLC tumor samples. EGFR protein expression evaluated by IHC correlates significantly with FISH results; best correlation is shown for 31G7 using scoring method B.Conclusion:Our advice is to use Dako PharmDx, 31G7 or 2.1E1 in IHC and confirm these data by FISH analysis to facilitate more patients for EGFR specific treatments concerning their EGFR expression pattern.

Rating:

Share or cite this content

Citations should be made in the following way:
R. Gaber, I. Watermann, C. Kugler, N. Reinmuth, R. M. Huber, P. Schnabel, E. Vollmer, M. Reck, T. Goldmann (Borstel, Großhansdorf, Borstel, Lübeck, Kiel, Großhansdorf, Munich, Heidelberg, Germany; Alexandria, Egypt). Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level?. Eur Respir J 2014; 44: Suppl. 58, 506

Member's Comments

No comment yet.

Related content which might interest you: Expression analysis of miR-21 in Bulgarian patients with non-small cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Comprehensive evaluation of nuclear factor-κΒ expression patterns in non-small cell lung cancer Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015 Simultaneous EGFR and VEGF alterations in non-small cell lung carcinoma based on tissue microarrays Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Significance of expression of TGF-β in pulmonary metastasis in non-small cell lung cancer tissues Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Prognostic value of survivin gene promoter polymorphisms in non-small cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Differences in expression and prognostic values of p16(ink) and VEGF in squamous and adenocarcinoma of the lung Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Immunohistochemical expression of nuclear factor kappa-B/p65 and cyclooxygenase-2 in non-small cell lung cancer patients: Prognostic value and impact on survival Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 beta-F1-ATPase expression as a prognostic factor for resected non-small cell lung cancer Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Proapoptotic effects of PAI-1 protein on lung and prostate cancer cells Source: Annual Congress 2013 –Basic research on lung cancer Year: 2013 A tissue microarray analysis on the role of chromosome 7 multiplication regarding the EGFR expression in non-small cell lung carcinomas Source: International Congress 2016 – Molecular targets in pulmonary disease Year: 2016 EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC) Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Polymorphism of HLA-G gene promotor in patients with non small cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 RT-PCR expression of EML4-ALK oncogene in Bulgarian patients with non-small cell lung cancers Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Molecular signatures of non-small cell lung cancer (NSCLC) obtained from gene expression profiling of the benign bronchial mucosa of smokers with and without NSCLC Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer Year: 2013 Investigation of survivin gene expression in non small cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 CD33+CD14-CD11b+CD66b+CD15+VEGFR-1hi myeloid derived suppressor cells and their clinical relevance in non-small cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 The prognostic impact of PD1 and PDL1 expression in non-small cell lung cancer Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Evaluation of predictive and therapeutic value of WSX1/IL27 axis in non-small cell lung cancer (NSCLC) Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 Cytological samples for the study of EGFR, KRAS and ALK mutations in non-small cell lung cancer Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013 Expression and clinical significance of S100 calcium binding protein A2 in lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer II Year: 2016